These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Horita N; Goto A; Shibata Y; Ota E; Nakashima K; Nagai K; Kaneko T Cochrane Database Syst Rev; 2017 Feb; 2(2):CD012066. PubMed ID: 28185242 [TBL] [Abstract][Full Text] [Related]
7. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials. Lai CC; Chen CH; Lin CYH; Wang CY; Wang YH Int J Chron Obstruct Pulmon Dis; 2019; 14():1539-1548. PubMed ID: 31371939 [TBL] [Abstract][Full Text] [Related]
8. Stepwise management of COPD: What is next after bronchodilation? Miravitlles M; Matsunaga K; Dreher M Ther Adv Respir Dis; 2023; 17():17534666231208630. PubMed ID: 37936381 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859 [TBL] [Abstract][Full Text] [Related]
10. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease. Maqsood U; Ho TN; Palmer K; Eccles FJ; Munavvar M; Wang R; Crossingham I; Evans DJ Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012930. PubMed ID: 30839102 [TBL] [Abstract][Full Text] [Related]
11. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. Vanfleteren L; Fabbri LM; Papi A; Petruzzelli S; Celli B Int J Chron Obstruct Pulmon Dis; 2018; 13():3971-3981. PubMed ID: 30587953 [TBL] [Abstract][Full Text] [Related]
12. Clinical Characteristics, Treatment Persistence, and Outcomes Among Patients With COPD Treated With Single- or Multiple-Inhaler Triple Therapy: A Retrospective Analysis in Spain. Alcázar-Navarrete B; Jamart L; Sánchez-Covisa J; Juárez M; Graefenhain R; Sicras-Mainar A Chest; 2022 Nov; 162(5):1017-1029. PubMed ID: 35787391 [TBL] [Abstract][Full Text] [Related]
13. A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid. Miravitlles M; Verhamme K; Calverley PMA; Dreher M; Bayer V; Gardev A; de la Hoz A; Wedzicha J; Price D Int J Chron Obstruct Pulmon Dis; 2022; 17():545-558. PubMed ID: 35309285 [TBL] [Abstract][Full Text] [Related]
14. Role of Long-Acting Muscarinic Antagonist/Long-Acting β Petite SE Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560 [TBL] [Abstract][Full Text] [Related]
15. Triple Inhaler versus Dual Bronchodilator Therapy in COPD: Real-World Effectiveness on Mortality. Suissa S; Dell'Aniello S; Ernst P COPD; 2022 Dec; 19(1):1-9. PubMed ID: 34544314 [TBL] [Abstract][Full Text] [Related]
16. Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England. Rothnie KJ; Joksaite S; Sansbury LB; Compton C; Di Boscio V; Ismaila AS Int J Chron Obstruct Pulmon Dis; 2022; 17():1455-1466. PubMed ID: 35769225 [TBL] [Abstract][Full Text] [Related]
17. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Nannini LJ; Lasserson TJ; Poole P Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD006829. PubMed ID: 22972099 [TBL] [Abstract][Full Text] [Related]
18. Current appraisal of single inhaler triple therapy in COPD. Lipworth B; Kuo CR; Jabbal S Int J Chron Obstruct Pulmon Dis; 2018; 13():3003-3009. PubMed ID: 30319248 [TBL] [Abstract][Full Text] [Related]
19. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy. Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905 [TBL] [Abstract][Full Text] [Related]
20. Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers? Tariq SM; Thomas EC Int J Chron Obstruct Pulmon Dis; 2017; 12():1877-1882. PubMed ID: 28694698 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]